Market capitalization | $598.31m |
Enterprise Value | $594.86m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-112.49m |
Free Cash Flow (TTM) Free Cash Flow | $-92.26m |
Cash position | $20.72m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
7 Analysts have issued a Humacyte forecast:
7 Analysts have issued a Humacyte forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -8.80 -8.80 |
17%
17%
|
|
EBITDA | -104 -104 |
19%
19%
|
EBIT (Operating Income) EBIT | -112 -112 |
19%
19%
|
Net Profit | -153 -153 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.
Head office | United States |
CEO | Laura Niklason |
Employees | 183 |
Founded | 2004 |
Website | humacyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.